An 8-Week Self-Administered At-Home Behavioral Skills-Based Virtual Reality Program for Chronic Low Back Pain: Double-Blind, Randomized, Placebo-Controlled Trial Conducted During COVID-19
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background: Chronic low back pain is the most prevalent chronic pain condition worldwide and access to behavioral pain treatment is limited. Virtual reality (VR) is an immersive technology that may provide effective behavioral therapeutics for chronic pain. Objective: We aimed to conduct a double-blind, parallel-arm, single-cohort, remote, randomized placebo-controlled trial for a self-administered behavioral skills-based VR program in community-based individuals with self-reported chronic low back pain during the COVID-19 pandemic. Methods: A national online convenience sample of individuals with self-reported nonmalignant low back pain with duration of 6 months or more and with average pain intensity of 4 or more/10 was enrolled and randomized 1:1 to 1 of 2 daily (56-day) VR programs: (1) EaseVRx (immersive pain relief skills VR program); or (2) Sham VR (2D nature content delivered in a VR headset). Objective device use data and self-reported data were collected. The primary outcomes were the between-group effect of EaseVRx versus Sham VR across time points, and the between–within interaction effect representing the change in average pain intensity and pain-related interference with activity, stress, mood, and sleep over time (baseline to end-of-treatment at day 56). Secondary outcomes were global impression of change and change in physical function, sleep disturbance, pain self-efficacy, pain catastrophizing, pain acceptance, pain medication use, and user satisfaction. Analytic methods included intention-to-treat and a mixed-model framework. Results: The study sample was 179 adults (female: 76.5%, 137/179; Caucasian: 90.5%, 162/179; at least some college education: 91.1%, 163/179; mean age: 51.5 years [SD 13.1]; average pain intensity: 5/10 [SD 1.2]; back pain duration ≥5 years: 67%, 120/179). No group differences were found for any baseline variable or treatment engagement. User satisfaction ratings were higher for EaseVRx versus Sham VR (P<.001). For the between-groups factor, EaseVRx was superior to Sham VR for all primary outcomes (highest P value=.009), and between-groups Cohen d effect sizes ranged from 0.40 to 0.49, indicating superiority was moderately clinically meaningful. For EaseVRx, large pre–post effect sizes ranged from 1.17 to 1.3 and met moderate to substantial clinical importance for reduced pain intensity and pain-related interference with activity, mood, and stress. Between-group comparisons for Physical Function and Sleep Disturbance showed superiority for the EaseVRx group versus the Sham VR group (P=.022 and .013, respectively). Pain catastrophizing, pain self-efficacy, pain acceptance, prescription opioid use (morphine milligram equivalent) did not reach statistical significance for either group. Use of over-the-counter analgesic use was reduced for EaseVRx (P<.01) but not for Sham VR. Conclusions: EaseVRx had high user satisfaction and superior and clinically meaningful symptom reduction for average pain intensity and pain-related interference with activity, mood, and stress compared to sham VR. Additional research is needed to determine durability of treatment effects and to characterize mechanisms of treatment effects. Home-based VR may expand access to effective and on-demand nonpharmacologic treatment for chronic low back pain. Trial Registration: ClinicalTrials.gov NCT04415177; https://clinicaltrials.gov/ct2/show/NCT04415177 International Registered Report Identifier (IRRID): RR2-10.2196/25291
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lakens, D. (2013) · Frontiers in Psychology · doi:10.3389/fpsyg.2013.00863 · Cited by 10,303
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Katz, N. P., Kerns, R. D., Stucki, G., Allen, R. R., Bellamy, N., et al. (2005) · Pain · doi:10.1016/j.pain.2004.09.012 · Cited by 3,732
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., Cleeland, C., Dionne, R., Farrar, J. T., Galer, B. S., et al. (2003) · Pain · doi:10.1016/j.pain.2003.08.001 · Cited by 3,510
Eysenbach, G. (2005) · Journal of Medical Internet Research · doi:10.2196/jmir.7.1.e11 · Cited by 2,524
Prevention and treatment of low back pain: evidence, challenges, and promising directions
Foster, N. E., Anema, J. R., Cherkin, D., Chou, R., Cohen, S. P., Gross, D. P., Ferreira, P. H., Fritz, J. M., Koes, B. W., Peul, W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30489-6 · Cited by 2,398
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000251 · Cited by 2,296
Psychological therapies for the management of chronic pain (excluding headache) in adults
Williams, A. C. D. C., Eccleston, C., & Morley, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007407.pub3 · Cited by 1,634
The Rising Prevalence of Chronic Low Back Pain
Freburger, J. K., Holmes, G. M., Agans, R. P., Jackman, A. M., Darter, J. D., Wallace, A. S., Castel, L. D., Kalsbeek, W. D., & Carey, T. S. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.543 · Cited by 1,507
Detecting and monitoring depression with a two-item questionnaire (PHQ-2)
Löwe, B., Kroenke, K., & Gräfe, K. (2005) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2004.09.006 · Cited by 1,473 · cited 1×
“Moderate depressive symptoms as indicated by the Patient Health Questionnaire-2 (PHQ-2 [44,45]) depression screen score of 2 or more.”
Yu, L., Buysse, D. J., Germain, A., Moul, D. E., Stover, A., Dodds, N. E., Johnston, K. L., & Pilkonis, P. A. (2012) · Behavioral Sleep Medicine · doi:10.1080/15402002.2012.636266 · Cited by 1,241 · cited 1×
“Physical Function and Sleep Disturbance (PROMIS) The NIH Physical Function and Sleep Disturbance (PROMIS) [55] short-form measures were used to assess physical function (version 6b) [56] and sleep disturbance (version 6a) [57] over the past 7 days.”
Cited by
The Influence of Wearables on Health Care Outcomes in Chronic Disease: Systematic Review
Mattison, G., Canfell, O., Forrester, D., Dobbins, C., Smith, D., Töyräs, J., & Sullivan, C. (2022) · Journal of Medical Internet Research · doi:10.2196/36690 · Cited by 171
Brea-Gómez, B., Torres-Sánchez, I., Ortiz-Rubio, A., Calvache-Mateo, A., Cabrera-Martos, I., López-López, L., & Valenza, M. C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182211806 · Cited by 98
“Regarding the interventions, three studies c mpared VR with no intervention [7,27,28], two studies with a place o [31,33], and other study with oral treatment (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), tramadol, and duloxetine) [38].”
BackgroundMethodInfluentialEccleston, C., Fisher, E., Liikkanen, S., Sarapohja, T., Stenfors, C., Jääskeläinen, S. K., Rice, A. S. C., Mattila, L., Blom, T., & Bratty, J. R. (2022) · Pain · doi:10.1097/j.pain.0000000000002617 · Cited by 64
Ziadni, M. S., Gonzalez-Castro, L., Anderson, S., Krishnamurthy, P., & Darnall, B. D. (2021) · Journal of Medical Internet Research · doi:10.2196/29672 · Cited by 59
“The enrollment rate was 53.1% (104/196), which is five times higher than that observed in other studies [12,77] and stands as an index of both the inclusivity of the study protocol (few exclusionary criteria; all types of chronic pain) and the convenience of a single-session pain treatment study.”
InfluentialSelf-citationMauck, M. C., Aylward, A. F., Barton, C. E., Birckhead, B., Carey, T., Dalton, D. M., Fields, A. J., Fritz, J., Hassett, A. L., Hoffmeyer, A., et al. (2022) · PAIN Reports · doi:10.1097/pr9.0000000000001019 · Cited by 49
Self-citationLi, R., Li, Y., Kong, Y., Li, H., Hu, D., Fu, C., & Wei, Q. (2024) · Journal of Medical Internet Research · doi:10.2196/45406 · Cited by 48
“In total, 19 RCTs provided available data that were pooled into a meta-analysis (Figure 3 [19-22 , 50-60 50-60,”
Găină, M.-A., Szalontay, A. S., Ștefănescu, G., Bălan, G. G., Ghiciuc, C. M., Boloș, A., Găină, A.-M., & Ștefănescu, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061670 · Cited by 44
“However, patient opioid analgesics requirements were not significantly influenced in any of the two interventions [21].”
BackgroundJanela, D., Costa, F., Molinos, M., Moulder, R. G., Lains, J., Francisco, G. E., Bento, V., Cohen, S. P., & Correia, F. D. (2022) · Journal of Pain Research · doi:10.2147/jpr.s343308 · Cited by 33
Merlot, B., Elie, V., Périgord, A., Husson, Z., Jubert, A., Chanavaz-Lacheray, I., Dennis, T., Cotty-Eslous, M., & Roman, H. (2023) · Journal of Medical Internet Research · doi:10.2196/47869 · Cited by 24
“This study also confirmed the effect of VR itself (digital control) when associated with nature sounds, which is already used to reduce pain during surgery or for patients in intensive care [39,40]: its immersive effect has a direct impact on pain as observed in previous work [22,28,29,41-51].”
InfluentialOut of Control: How to Design Digital Placebos
Blease, C. (2023) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-023-00290-w · Cited by 15
“A recent FDA-approved virtual reality intervention for lower back pain, embedding a CBT-based program, offers another instructive example of the current limitations associated with current digital placebo design [21].”
Background
Metadata
- Authors
- Garcia, L. M., Birckhead, B. J., Krishnamurthy, P., Sackman, J., Mackey, I. G., Louis, R. G., Salmasi, V., Maddox, T., & Darnall, B. D.
- Venue
- Journal of Medical Internet Research
- Publisher
- JMIR Publications Inc.
- Published
- 2021-02-22
- Volume
- 23
- Issue
- 2
- Pages
- e26292
- ISSN
- 1438-8871 (ISSN-L)
- OpenAlex
- W3119643745
- Cited by
- 218
- References
- 29
- FWCI
- 18.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.